CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
June 2015—Ventana Medical Systems has entered into a master collaboration agreement with Astellas Pharma, a research-and-development–driven pharmaceutical company headquartered in Japan, to develop novel automated tissue diagnostics in support of therapeutic compounds in development.
Initial projects related to this agreement will support early-stage clinical trials for the Astellas therapeutic compound ASP5878, a novel small-molecule fibroblast growth factor receptor inhibitor that has been shown to block the kinase activities of FGFR1, FGFR2, FGFR3, and FGFR4. Ventana will develop, in parallel, an immunohistochemistry test identifying FGF19 in certain solid tumors. Financial terms of the agreement were not disclosed.
Ventana Medical Systems, 520-887-2155